Eric D. Jacobsen

18.2k total citations · 3 hit papers
145 papers, 4.5k citations indexed

About

Eric D. Jacobsen is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Eric D. Jacobsen has authored 145 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Pathology and Forensic Medicine, 64 papers in Oncology and 50 papers in Genetics. Recurrent topics in Eric D. Jacobsen's work include Lymphoma Diagnosis and Treatment (97 papers), Chronic Lymphocytic Leukemia Research (50 papers) and CAR-T cell therapy research (33 papers). Eric D. Jacobsen is often cited by papers focused on Lymphoma Diagnosis and Treatment (97 papers), Chronic Lymphocytic Leukemia Research (50 papers) and CAR-T cell therapy research (33 papers). Eric D. Jacobsen collaborates with scholars based in United States, France and Italy. Eric D. Jacobsen's co-authors include Steven M. Horwitz, Arnold S. Freedman, Nancy L. Bartlett, Ranjana H. Advani, Ivana N. Micallef, Mark W. Clemens, David C. Fisher, Owen A. O’Connor, John M. McCarty and Patrick J. Stiff and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Infectious Diseases.

In The Last Decade

Eric D. Jacobsen

141 papers receiving 4.4k citations

Hit Papers

Phase III Prospective Randomized Double-Blind Placebo-Con... 2009 2026 2014 2020 2009 2011 2018 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma
    2009 512 citations John F. DiPersio, Ivana N. Micallef et al. Journal of Clinical Oncology profile →
  2. Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
    2011 439 citations Owen A. O’Connor, Barbara Pro et al. Journal of Clinical Oncology profile →
  3. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease
    2018 313 citations Eric D. Jacobsen et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric D. Jacobsen United States 30 2.6k 1.9k 1.1k 953 792 145 4.5k
Naokuni Uike Japan 37 1.8k 0.7× 1.8k 0.9× 2.5k 2.2× 852 0.9× 743 0.9× 151 5.1k
Claudio Agostinelli Italy 30 2.0k 0.8× 1.5k 0.8× 992 0.9× 585 0.6× 624 0.8× 151 3.3k
Yoshitoyo Kagami Japan 35 2.3k 0.9× 1.9k 1.0× 1.0k 0.9× 705 0.7× 739 0.9× 102 3.9k
C. Cameron Yin United States 37 1.7k 0.6× 1.4k 0.7× 841 0.8× 1.7k 1.7× 950 1.2× 226 4.6k
Tomohiro Kinoshita Japan 35 2.3k 0.9× 2.0k 1.0× 852 0.8× 937 1.0× 1.1k 1.4× 158 4.4k
ES Jaffe United States 33 2.9k 1.1× 2.4k 1.2× 1.9k 1.7× 1.1k 1.2× 544 0.7× 57 5.0k
Kennosuke Karube Japan 31 1.8k 0.7× 1.3k 0.6× 1.2k 1.1× 720 0.8× 550 0.7× 136 3.2k
Marie‐Hélène Delfau‐Larue France 39 2.7k 1.0× 1.8k 0.9× 1.5k 1.4× 645 0.7× 474 0.6× 118 4.3k
William G. Morice United States 34 1.3k 0.5× 991 0.5× 1.1k 1.0× 1.2k 1.2× 845 1.1× 90 3.4k
Harald Stein Germany 33 1.9k 0.7× 1.5k 0.8× 1.1k 1.0× 672 0.7× 941 1.2× 53 4.0k

Countries citing papers authored by Eric D. Jacobsen

Since Specialization
Citations

This map shows the geographic impact of Eric D. Jacobsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric D. Jacobsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric D. Jacobsen more than expected).

Fields of papers citing papers by Eric D. Jacobsen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric D. Jacobsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric D. Jacobsen. The network helps show where Eric D. Jacobsen may publish in the future.

Co-authorship network of co-authors of Eric D. Jacobsen

This figure shows the co-authorship network connecting the top 25 collaborators of Eric D. Jacobsen. A scholar is included among the top collaborators of Eric D. Jacobsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric D. Jacobsen. Eric D. Jacobsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Herling, Marco, Claire Dearden, Francesco Zaja, et al.. (2024). Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood Advances. 8(4). 842–845. 2 indexed citations
3.
Zinzani, Pier Luigi, Eric D. Jacobsen, Jasmine Zain, et al.. (2024). Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial. Blood. 144(Supplement 1). 3061–3061. 4 indexed citations
4.
Merrill, Mwanasha H., et al.. (2024). Real-World Evidence for Duvelisib and Romidepsin Combination in Patients with Relapsed/Refractory Peripheral T-Cell Lymphomas. Blood. 144(Supplement 1). 4453–4453. 2 indexed citations
5.
Ryan, Christine E., Danielle M. Brander, Paul M. Barr, et al.. (2023). A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia. 37(4). 835–842. 2 indexed citations
6.
Kim, Y. H., M. Bagot, Pablo L. Ortiz‐Romero, et al.. (2023). LACUTAMAB IN PATIENTS WITH ADVANCED MYCOSIS FUNGOIDES (MF): EFFICACY RESULTS ACCORDING TO UPDATED LYMPH NODE (LN) CLASSIFICATION IN THE TELLOMAK STUDY. Hematological Oncology. 41(S2). 196–197. 2 indexed citations
7.
Davids, Matthew S., Haesook T. Kim, Alexandra Savell, et al.. (2018). Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study. The Lancet Haematology. 6(1). e38–e47. 90 indexed citations
8.
Fisher, David C., et al.. (2018). Cutaneous Involvement of Hematologic Malignancies. Hematology/Oncology Clinics of North America. 33(1). 163–172. 3 indexed citations
9.
Davids, Matthew S., Haesook T. Kim, Alexandra Savell, et al.. (2017). Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood. 130. 4317–4317. 1 indexed citations
10.
Foss, Francine M., Ranjana H. Advani, Madeleine Duvic, et al.. (2014). A Phase II trial of Belinostat ( PXD 101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma. British Journal of Haematology. 168(6). 811–819. 161 indexed citations
11.
Shaughnessy, Paul, Joseph P. Uberti, Steven M. Devine, et al.. (2012). Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin’s lymphoma and multiple myeloma: results from the expanded access program. Bone Marrow Transplantation. 48(6). 777–781. 29 indexed citations
12.
O’Connor, Owen A., Barbara Pro, Lauren Pinter‐Brown, et al.. (2011). Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study. Journal of Clinical Oncology. 29(9). 1182–1189. 439 indexed citations breakdown →
13.
Amrein, Philip C., Eyal C. Attar, Tak Takvorian, et al.. (2011). Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. Clinical Cancer Research. 17(9). 2977–2986. 100 indexed citations
14.
Doyle, Leona A., Justin P. Annes, Michael F. Murray, et al.. (2010). Erdheim-Chester disease presenting with cutaneous involvement: a case report and literature review. Journal of Cutaneous Pathology. 38(3). 280–285. 30 indexed citations
15.
Witzig, Thomas E., Craig B. Reeder, Betsy LaPlant, et al.. (2010). A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 25(2). 341–347. 254 indexed citations
16.
DiPersio, John F., Ivana N. Micallef, Patrick J. Stiff, et al.. (2009). Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 27(28). 4767–4773. 512 indexed citations breakdown →
17.
Armand, Philippe, Haesook T. Kim, Corey Cutler, et al.. (2008). Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning. Journal of Clinical Oncology. 26(35). 5767–5774. 80 indexed citations
18.
Jacobsen, Eric D. & Karaba N. Nataraja. (2008). Cisgenics - Facilitating the second green revolution in India by improved traditional plant breeding. Current Science. 94(1). 1365–1366. 12 indexed citations
19.
Crump, Michael, Bertrand Coiffier, Eric D. Jacobsen, et al.. (2008). Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Annals of Oncology. 19(5). 964–969. 139 indexed citations
20.
Bruinenberg, P. M., Eric D. Jacobsen, & R.G.F. Visser. (1995). Starch from genetically engineered crops.. Chemistry & Industry. 21(21). 881–884. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Naokuni Uike Breakdown of academic impact, for papers by Claudio Agostinelli Breakdown of academic impact, for papers by Yoshitoyo Kagami Breakdown of academic impact, for papers by C. Cameron Yin Breakdown of academic impact, for papers by Tomohiro Kinoshita Breakdown of academic impact, for papers by ES Jaffe Breakdown of academic impact, for papers by Kennosuke Karube Breakdown of academic impact, for papers by Marie‐Hélène Delfau‐Larue Breakdown of academic impact, for papers by William G. Morice Breakdown of academic impact, for papers by Harald Stein
Rankless by CCL
2026